Admescope is a preclinical contract research organization that provides tailored ADME-Tox and DMPK services for drug discovery and development companies. The company supports various drug modalities—including small molecules, peptides, oligonucleotides, antibodies, and antibody-drug conjugates—with services spanning drug metabolism, pharmacokinetics, drug interactions, and quantitative bioanalysis.
Subscribe to see ADME, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ADME, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $24,800 in January 2017. Xcout tracks 1 named person at ADME, Inc., including Outi Kontkanen (CEO).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $24,800 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of ADME, Inc.'s closest competitors — see the full list of competitors and alternatives →
Analiza provides physicochemical ADME screening and in-vitro ADME properties testing services for the life sciences industry.
WuXi Biology provides a comprehensive spectrum of preclinical biology services and solutions for drug discovery, supporting clients from target discovery and validation to hit finding, lead optimization, and candidate selection. The company offers specialized platforms and expertise across major disease areas and therapeutic modalities, including small molecules, oligonucleotides, peptides, and antibodies.
Sai Life Sciences operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) providing services from drug discovery to manufacturing. It serves pharmaceutical and biotech companies by offering capabilities in synthetic medicinal chemistry, biology, drug metabolism and pharmacokinetics, process development, and drug substance manufacturing.
Celerion operates as an early-phase clinical research contract research organization (CRO) providing bioanalytical sciences, drug development, and regulatory services to pharmaceutical and biotechnology companies. The company conducts early-phase clinical trials, pharmacokinetic and pharmacodynamic analysis, immunogenicity testing, and biomarker analysis to accelerate drug development processes.
Meadowhawk Biolabs, Inc. is a preclinical contract research organization that provides expert bioanalysis and related research services.
Biotoxtech Co., Ltd. is a South Korean contract research organization that provides nonclinical drug-development services, including toxicology, pharmacology, pharmacokinetics, pathology, and related GLP studies. It serves pharmaceutical and biotechnology companies developing drugs and other biomedical products.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about ADME, Inc.? Suggest a correction · Work at ADME, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.